# EDGAR Filing Document

**Accession Number:** 0001698008
**File Stem:** 0001193125-26-041544
**Filing Date:** 2026-2
**Character Count:** 19162
**Document Hash:** 12706e191bcecffcc96b126c2f8bdc7c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-041544.hdr.sgml**: 20260206

**ACCESSION NUMBER**: 0001193125-26-041544

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260204

**FILED AS OF DATE**: 20260206

**DATE AS OF CHANGE**: 20260206

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Hebert Peter
- **CENTRAL INDEX KEY:** 0001683771

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26609142

**MAIL ADDRESS:**
- **STREET 1:** C/O LUX VENTURES
- **STREET 2:** 295 MADISON AVE, 24TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lux Ventures V, L.P.
- **CENTRAL INDEX KEY:** 0001698008

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26609141

**BUSINESS ADDRESS:**
- **STREET 1:** C/O LUX CAPITAL MANAGEMENT
- **STREET 2:** 295 MADISON AVENUE, 24TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** (646) 475-4385

**MAIL ADDRESS:**
- **STREET 1:** C/O LUX CAPITAL MANAGEMENT
- **STREET 2:** 295 MADISON AVENUE, 24TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lux Venture Partners V, LLC
- **CENTRAL INDEX KEY:** 0001698118

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26609144

**BUSINESS ADDRESS:**
- **STREET 1:** C/O LUX CAPITAL MANAGEMENT
- **STREET 2:** 920 BROADWAY, 11TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** (646) 475-4385

**MAIL ADDRESS:**
- **STREET 1:** C/O LUX CAPITAL MANAGEMENT
- **STREET 2:** 920 BROADWAY, 11TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lux Total Opportunities, L.P.
- **CENTRAL INDEX KEY:** 0001864658

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26609139

**BUSINESS ADDRESS:**
- **STREET 1:** 920 BROADWAY, 11TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** 646-475-4385

**MAIL ADDRESS:**
- **STREET 1:** 920 BROADWAY, 11TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Wolfe Josh
- **CENTRAL INDEX KEY:** 0001830001

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26609143

**MAIL ADDRESS:**
- **STREET 1:** C/O LUX HEALTH TECH ACQUISITION CORP.
- **STREET 2:** 920 BROADWAY, 11TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lux Co-Invest Opportunities II, L.P.
- **CENTRAL INDEX KEY:** 0001783916

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26609140

**BUSINESS ADDRESS:**
- **STREET 1:** 920 BROADWAY, 11TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** (646)475-4385

**MAIL ADDRESS:**
- **STREET 1:** 920 BROADWAY, 11TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Eikon Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001861123
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 842807586
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 230 HARRIET TUBMAN WAY
- **CITY:** MILLBRAE
- **STATE:** CA
- **ZIP:** 94030
- **BUSINESS PHONE:** 341-777-0566

**MAIL ADDRESS:**
- **STREET 1:** 230 HARRIET TUBMAN WAY
- **CITY:** MILLBRAE
- **STATE:** CA
- **ZIP:** 94030

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lux Venture Partners V, LLC<br><sub>(Last) (First) (Middle)</sub><br>920 BROADWAY, 11TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10010<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Wolfe Josh<br><sub>(Last) (First) (Middle)</sub><br>C/O EIKON THERAPEUTICS<br>230 HARRIET TUBMAN WAY<br><sub>(Street)</sub><br>MILLBRAE, CA 94030<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Hebert Peter<br><sub>(Last) (First) (Middle)</sub><br>920 BROADWAY, 11TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10010<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lux Ventures V, L.P.<br><sub>(Last) (First) (Middle)</sub><br>920 BROADWAY, 11TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10010<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lux Co-Invest Opportunities II, L.P.<br><sub>(Last) (First) (Middle)</sub><br>920 BROADWAY, 11TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10010<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lux Total Opportunities, L.P.<br><sub>(Last) (First) (Middle)</sub><br>920 BROADWAY, 11TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10010<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-04 |  | P |  | 138888 | A | $18.00 | 138888 | I | See Footnote<sup>(1)</sup> |
| Common Stock | 2026-02-04 |  | P |  | 138888 | A | $18.00 | 138888 | I | See Footnote<sup>(2)</sup> |
| Common Stock | 2026-02-06 |  | C |  | 2387705 | A | <sup>(3)(4)</sup> | 2387705 | I | See Footnote<sup>(5)</sup> |
| Common Stock | 2026-02-06 |  | C |  | 1151540 | A | <sup>(4)(6)(7)</sup> | 1290428 | I | See Footnote<sup>(1)</sup> |
| Common Stock | 2026-02-06 |  | C |  | 2155765 | A | <sup>(6)(7)(8)(9)(10)</sup> | 2294653 | I | See Footnote<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series A Preferred Stock | <sup>(3)</sup> | 2026-02-06 |  | C |  |  | 10000000 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 1340878 | <sup>(3)</sup> | 0 | I | See Footnote<sup>(5)</sup> |
| Series A-1 Preferred Stock | <sup>(4)</sup> | 2026-02-06 |  | C |  |  | 7807026 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 1046827 | <sup>(4)</sup> | 0 | I | See Footnote<sup>(5)</sup> |
| Series A-1 Preferred Stock | <sup>(4)</sup> | 2026-02-06 |  | C |  |  | 2502252 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 335521 | <sup>(4)</sup> | 0 | I | See Footnote<sup>(1)</sup> |
| Series B Preferred Stock | <sup>(6)</sup> | 2026-02-06 |  | C |  |  | 796380 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 106785 | <sup>(6)</sup> | 0 | I | See Footnote<sup>(1)</sup> |
| Series B Preferred Stock | <sup>(6)</sup> | 2026-02-06 |  | C |  |  | 530920 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 71190 | <sup>(6)</sup> | 0 | I | See Footnote<sup>(2)</sup> |
| Series B-1 Preferred Stock | <sup>(7)</sup> | 2026-02-06 |  | C |  |  | 5289322 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 709234 | <sup>(7)</sup> | 0 | I | See Footnote<sup>(1)</sup> |
| Series B-1 Preferred Stock | <sup>(7)</sup> | 2026-02-06 |  | C |  |  | 3526215 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 472822 | <sup>(7)</sup> | 0 | I | See Footnote<sup>(2)</sup> |
| Series C Preferred Stock | <sup>(8)</sup> | 2026-02-06 |  | C |  |  | 303360 | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 40677 | <sup>(8)</sup> | 0 | I | See Footnote<sup>(2)</sup> |
| Series C-1 Preferred Stock | <sup>(9)</sup> | 2026-02-06 |  | C |  |  | 1450614 | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 194510 | <sup>(9)</sup> | 0 | I | See Footnote<sup>(2)</sup> |
| Series D Preferred Stock | <sup>(10)</sup> | 2026-02-06 |  | C |  |  | 10266152 | <sup>(10)</sup> | <sup>(10)</sup> | Common Stock | 1376566 | <sup>(10)</sup> | 0 | I | See Footnote<sup>(2)</sup> |

---

### Footnotes:

(1) These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.

(2) These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein.

(3) The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date.

(4) The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.

(5) These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. The Individual Lux Managers are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. Each of LVPV and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein.

(6) The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.

(7) The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.

(8) The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.

(9) The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.

(10) The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.

**Signature:** /s/ Josh Wolfe  
**Date:** 2026-02-06

**Signature:** /s/ Peter Hebert  
**Date:** 2026-02-06

**Signature:** Lux Ventures V, L.P., By: Lux Venture Partners V, LLC, its General Partner, By: Peter Hebert, Managing Member /s/ Peter Hebert  
**Date:** 2026-02-06

**Signature:** Lux Venture Partners V, LLC, By: Peter Hebert, Managing Member /s/ Peter Hebert  
**Date:** 2026-02-06

**Signature:** Lux Co-Invest Opportunities II, L.P., By: Lux Co-Invest Partners II, LLC, its General Partner, By: Peter Hebert, Managing Member /s/ Peter Hebert  
**Date:** 2026-02-06

**Signature:** Lux Co-Invest Partners II, LLC, By: Peter Hebert, Managing Member /s/ Peter Hebert  
**Date:** 2026-02-06

**Signature:** Lux Total Opportunities, L.P., By: Lux Total Opportunities Partners, LLC, its General Partner, By: Peter Hebert, Managing Member /s/ Peter Hebert  
**Date:** 2026-02-06

**Signature:** Lux Total Opportunities Partners, LLC, By: Peter Hebert, Managing Member /s/ Peter Hebert  
**Date:** 2026-02-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**